The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Feasibility of an Ingestible Sensor-Based System for Monitoring Adherence to Tuberculosis Therapy
Open accessAbstract
Poor adherence to tuberculosis (TB) treatment hinders the individual's recovery and threatens public health. Currently, directly observed therapy (DOT) is the standard of care; however, high sustaining costs limit its availability, creating a need for more practical adherence confirmation methods. Techniques such as video monitoring and devices to time-register the opening of pill bottles are unable to confirm actual medication ingestions. A novel approach developed by Proteus Digital Health, Inc. consists of an ingestible sensor and an on-body wearable sensor; together, they electronically confirm unique ingestions and record the date/time of the ingestion. A feasibility study using an early prototype was conducted in active TB patients to determine the system's accuracy and safety in confirming co-ingestion of TB medications with sensors. Thirty patients completed 10 DOT visits and 1,080 co-ingestion events; the system showed 95.0% (95% CI 93.5-96.2%) positive detection accuracy, defined as the number of detected sensors divided by the number of transmission capable sensors administered. The specificity was 99.7% [95% CI 99.2-99.9%] based on three false signals recorded by receivers. The system's identification accuracy, defined as the number of correctly identified ingestible sensors divided by the number of sensors detected, was 100%. Of 11 adverse events, four were deemed related or possibly related to the device; three mild skin rashes and one complaint of nausea. The system's positive detection accuracy was not affected by the subjects' Body Mass Index (p = 0.7309). Study results suggest the system is capable of correctly identifying ingestible sensors with high accuracy, poses a low risk to users, and may have high patient acceptance. The system has the potential to confirm medication specific treatment compliance on a dose-by-dose basis. When coupled with mobile technology, the system could allow wirelessly observed therapy (WOT) for monitoring TB treatment as a replacement for DOT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and suggested this DMO can identify reasons for uncontrolled HTN and help patients achieve BP control [16-21].”
From Effectiveness of Digital Medicines to Improve Clinical Outcomes in Patients with Uncontrolled Hypertension and Type 2 Diabetes: Prospective, Open-Label, Cluster-Randomized Pilot Clinical Trial (2017) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Prior clinical studies demonstrated the accuracy, safety, and feasibility of using the DMO in patients across a range of medical conditions, including HTN and type 2 diabetes mellitus (T2DM)”
From Effectiveness of Digital Medicines to Improve Clinical Outcomes in Patients with Uncontrolled Hypertension and Type 2 Diabetes: Prospective, Open-Label, Cluster-Randomized Pilot Clinical Trial (2017) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, these uncontrolled studies did not focus on disease control.”
The cited source says what the claim attributes to it.
In the citing paper
“Ingestible sensors combined with or embedded in tablets may accurately determine taking adherence[23,24].”
From Adherence is associated with a favorable outcome after lung transplantation (2019) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McGuire, S. (2014) · Advances in Nutrition · doi:10.3945/an.114.007211 · Cited by 1,107
Gandhi, N. R., Nunn, P. P., Dheda, K. U. J., Schaaf, H. S., Zignol, M., van Soolingen, D., Jensen, P. A., & Bayona, J. N. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60410-2 · Cited by 1,042
Tuberculosis in New York City — Turning the Tide
Frieden, T. R., Fujiwara, P. I., Washko, R. M., & Hamburg, M. A. (1995) · New England Journal of Medicine · doi:10.1056/nejm199507273330406 · Cited by 644
Haynes, R. B., McKibbon, K. A., & Kanani, R. S. (1996) · The Lancet · doi:10.1016/s0140-6736(96)01073-2 · Cited by 643
(1923) · Public Health · doi:10.1016/s0033-3506(23)80379-1 · Cited by 459
Chaulk, C. P. (1998) · JAMA · doi:10.1001/jama.279.12.943 · Cited by 272
The TB epidemic from 1992 to 2002
Raviglione, M. C. (2003) · Tuberculosis · doi:10.1016/s1472-9792(02)00071-9 · Cited by 267
Promoting adherence to treatment for tuberculosis: the importance of direct observation
Frieden, T. R. (2007) · Bulletin of the World Health Organization · doi:10.2471/blt.06.038927 · Cited by 145
Promoting adherence to treatment for tuberculosis: the importance of direct observation.
Frieden, T. R., & Sbarbaro, J. A. (2007) · PubMed · doi:10.2471/06.038927 · Cited by 125
Dixon, W., Stradling, P., & Wootton, I. D. P. (1957) · The Lancet · doi:10.1016/s0140-6736(57)90006-5 · Cited by 122
Flagged first, then by citations
Cited by
Sorted by citations
Adherence in Hypertension: A Review of Prevalence, Risk Factors, Impact, and Management
Burnier, M., & Egan, B. M. (2019) · Circulation Research · doi:10.1161/circresaha.118.313220 · Cited by 878
Artificial intelligence biosensors: Challenges and prospects
Jin, X., Liu, C., Xu, T., Su, L., & Zhang, X. (2020) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2020.112412 · Cited by 399
A pH-responsive supramolecular polymer gel as an enteric elastomer for use in gastric devices
Zhang, S., Bellinger, A. M., Glettig, D. L., Barman, R. A., Lee, Y. L., Zhu, J., Cleveland, C., Montgomery, V. A., Gu, L., Nash, L. D., et al. (2015) · Nature Materials · doi:10.1038/nmat4355 · Cited by 328
Current Situation of Medication Adherence in Hypertension
Vrijens, B., Antoniou, S., Burnier, M., de la Sierra, A., & Volpe, M. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00100 · Cited by 292
Ingestible electronics for diagnostics and therapy
Steiger, C., Abramson, A., Nadeau, P., Chandrakasan, A. P., Langer, R., & Traverso, G. (2018) · Nature Reviews Materials · doi:10.1038/s41578-018-0070-3 · Cited by 281
Metadata
- Authors
- Belknap, R., Weis, S., Brookens, A., Au-Yeung, K. Y., Moon, G., DiCarlo, L., & Reves, R.
- Affiliations
- Denver Public Health (US)
- University of Washington (US)
- Proteus Digital Health (US)
- Corresponding author
- Belknap, Robert
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-01-07
- Volume
- 8
- Issue
- 1
- Pages
- e53373
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3538759
- OpenAlex
- W1988611386
- Cited by
- 160
- References
- 18
- Citations by year
- 2026: 5 · 2025: 10 · 2024: 7 · 2023: 6 · 2022: 20 · 2021: 12 · 2020: 22 · 2019: 16 · 2018: 11 · 2017: 19 · 2016: 18 · 2015: 11 · 2014: 1 · 2013: 2
- FWCI
- 9.05
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Health Professions › General Health Professions › Mobile Health and mHealth Applications
- Keywords
- tuberculosis, medication adherence, ingestible sensors, directly observed therapy, wearable sensors, detection accuracy, adverse events, body mass index
- MeSH terms
- Administration, Oral, Adult, Aged, Antitubercular Agents, Drug Administration Schedule, Feasibility Studies, Female, Humans, Male, Middle Aged, Prospective Studies, Public Health, Sensitivity and Specificity, Tuberculosis, Pulmonary, Biosensing Techniques, Body Mass Index, Drug Monitoring, Directly Observed Therapy, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
